A striking idea is starting to take hold in the most brutal corner of epilepsy care: instead of asking only whether ketamine “works,” clinicians may soon be able to ask a more practical question—who is it likely to help, right now? Personally, I think this shift is exactly what modern medicine should look like when the stakes are high: move from one-size-fits-all enthusiasm to targeted, signal-based decision-making. And in super-refractory status epilepticus, where time is measured in seizures and brain injury, even partial predictive power can feel like a lifeline.
What makes this particularly fascinating is that the predictive clues are not exotic. The signals reportedly come from two places doctors already touch constantly: the EEG and routine inflammatory blood markers. If you take a step back and think about it, this is an argument for “physiology-first” treatment—using what the body is already showing to guide what you inject.
Ketamine isn’t the whole story
Ketamine has been evaluated as an intravenous option for adults with super-refractory status epilepticus, a condition defined by persistence despite standard anesthetic-level therapy. In a small single-center retrospective study of 12 adults, about 58% achieved sustained response—seizure cessation without recurrence after complete withdrawal of anesthetic therapy. Adverse effects were generally described as mild, with transient liver enzyme elevation showing up in 42% of patients.
But here’s my take: the headline number matters, yet it’s almost the least interesting part of the study. In these patients, the real question is not whether ketamine can help in theory—it’s whether clinicians can stop guessing in the dark. Personally, I think a moderate response rate is exactly what you expect in a biologically heterogeneous emergency, where “super-refractory” can mean multiple underlying mechanisms wearing the same clinical mask.
What many people don’t realize is that a modest overall efficacy can coexist with strong subgroup effects. That’s often how breakthrough therapies behave when they’re deployed in conditions with mixed etiologies. This study suggests responders may not simply be “lucky”—they might be physiologically distinguishable.
Inflammation may be shaping the odds
The most striking separation between responders and non-responders, according to the report, involved inflammatory status at the onset of status epilepticus. Non-responders reportedly showed a markedly hyperinflammatory state, with composite indices—such as neutrophil-to-lymphocyte ratio, the Systemic Inflammation Response Index, and the Systemic Immune-Inflammation Index—higher in those who did not respond. From my perspective, this is the body whispering that the dominant driver of seizures might not be the same across patients.
What this really suggests is that ketamine—while pharmacologically potent—may be less able to override certain immune-driven cascades. Personally, I think that’s an important conceptual correction. Too often, we treat seizures like they’re purely electrical events, then wonder why anti-epileptic strategies fail when the immune system is actively stoking the fire.
This raises a deeper question: are we dealing with different “types” of super-refractory status? One interpretation is that in highly inflammatory cases, the brain environment becomes hostile to the intended pharmacologic effect, whether through cytokine signaling, blood-brain barrier changes, or downstream neuroinflammation. Another interpretation—equally plausible—is that inflammation is not the cause but a marker of a broader, more dangerous physiological trajectory.
People also tend to misunderstand inflammatory markers as mere lab noise. In my opinion, when multiple independent indices line up, it’s harder to dismiss them. Even if the causal chain isn’t fully proven, inflammation-related patterns could become a practical triage tool.
The EEG seems to “predict” the pharmacology
EEG findings reportedly echoed the inflammatory signal. A beta background pattern appeared more common among responders, while discontinuous and burst-suppression backgrounds were associated with poorer outcomes. Personally, I find this especially interesting because EEG is not just monitoring—it’s mapping the brain’s functional state in real time.
If you take a step back and think about it, the EEG patterns may be reflecting how “recoverable” cortical networks are. Ketamine may help when brain dynamics retain enough structure to be modulated. In contrast, discontinuous or burst-suppression patterns might represent a deeper level of network collapse where any NMDA-related modulation is too late or too small.
What this implies for practice is bigger than it sounds. EEG-based stratification could reduce the emotional whiplash that clinicians and families experience when an intervention fails after escalation. In an emergency, prognostic clarity is not just academic—it changes decisions about intensity, monitoring, and goals of care discussions.
A predictive score: KEOS as a decision tool
To operationalize these observations, the investigators created an exploratory Ketamine EEG Outcome Score (KEOS). The reported discrimination performance was notably high, with an area under the curve of 0.97, plus sensitivity of 100% and specificity of 85.7%. Personally, I think scores like this are both exciting and risky: exciting because they suggest a path to structured decision-making, risky because small retrospective samples can create a flattering picture of performance.
Still, the conceptual value is hard to ignore. A composite score that blends EEG signatures with biology moves the field toward “predict, then treat,” rather than “treat, then retrospectively explain.” Clinicians repeatedly face the uncomfortable reality that super-refractory status epilepticus is a syndrome, not a single mechanism. A tool like KEOS acknowledges that reality.
A detail I find especially interesting is that the score seems designed for monitoring and decision-making during prolonged refractory seizures. That’s exactly when a structured predictive framework is most needed—when the next step must be chosen under time pressure and incomplete information.
The real limitation: sample size and retrospective design
The study is small and retrospective, which means it should be treated as hypothesis-generating rather than practice-replacing. Personally, I think this is where medicine often gets derailed: promising signals get amplified in press releases, while the slower work of validation gets postponed.
With only 12 patients, the risk of overfitting or accidental imbalance is real. You can also imagine unmeasured confounders: differences in etiology, timing of ketamine administration, concurrent therapies, EEG interpretation variability, or the inflammatory baseline shaped by factors not captured in the dataset. Even the definition of “sustained response” can behave differently depending on how clinicians operationalize withdrawal and follow-up.
What people usually misunderstand about retrospective studies is that “significant” does not mean “safe to generalize.” It means “worth testing.” The strongest interpretation is not that KEOS is definitively accurate, but that the study identified plausible, biologically coherent predictors.
Why this trend matters beyond ketamine
Personally, I think the bigger story is what this implies for refractory epilepsy overall: treatment response may increasingly depend on the ability to phenotype disease in real time. EEG is already a workhorse; inflammatory markers are already available; together they offer a relatively accessible way to stratify patients.
This aligns with a broader trend in emergency neurology: moving toward biomarkers and composite risk frameworks that can inform escalation. In other words, the field is trying to stop treating “refractory” as a monolithic endpoint. Instead, it’s trying to treat it like a spectrum of physiological narratives.
From my perspective, the most important future development would be prospective multicenter validation that tests KEOS across different hospitals, EEG readers, and treatment protocols. If it holds up, it could become a pragmatic tool, not just a research finding.
My takeaway
Ketamine may offer meaningful seizure control for some adults with super-refractory status epilepticus, and this study suggests that response is not random. The most persuasive signal appears to come from the intersection of inflammatory biology and EEG network state—two domains that often get discussed separately in clinical practice. Personally, I think the most hopeful part is the emerging possibility of structured prediction: not just “try ketamine,” but “try ketamine when the physiology suggests it will matter.”
What this really suggests is that the next era of refractory epilepsy care will be less about heroic one-off interventions and more about mapping patient-specific mechanisms—even when you have minutes, not months, to act.
Would you like the article to read more like a sharp op-ed (more opinionated and punchy) or more like a clinical commentary (slightly more cautious and technical)?
